SAFFRON data de-risks global regulatory filings for Tagrisso+Orpathys in MET-driven post-Tagrisso EGFRm NSCLC, a high-unmet-need population. Watch for regulatory submissions in US/EU over next 6-12 months and potential peak sales contribution. The combination strengthens AstraZeneca's lung cancer franchise against competitive threats.
Drugs in focus
AZN drug pipeline →ORPATHYS
◆ Mixed Named in this 6-K- Impact
- Phase
- Approved in China (3 indications); global Phase 3 readout pending
- Time to market
- Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
- Next catalyst
- None dated
What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 17 $156.89entry
- T+1 · 3mo ago +2.05%α +2.72% · $160.10
- T+5 · 3mo ago +6.26%α +7.45% · $166.71
- T+20 · 2mo ago +4.39%α +5.92% · $163.78
- T+60 · 7d ago +20.72%α +23.48% · $189.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AstraZeneca announced positive Phase III SAFFRON trial results showing Tagrisso plus Orpathys significantly improved progression-free survival (PFS) and overall survival (OS) vs chemotherapy in EGFR-mutated NSCLC patients with MET-driven resistance after Tagrisso progression. This is the first global Phase III to show both PFS and OS benefit in this setting, supporting global regulatory submissions and reinforcing Tagrisso's backbone role in EGFRm lung cancer.
Key Facts
- SAFFRON Phase III trial met dual primary endpoint of PFS and key secondary endpoint of OS with statistical significance and clinical meaningfulness vs doublet platinum-based chemotherapy.
- Trial enrolled 338 patients across 230 centers in 29 countries; patients had EGFRm NSCLC with high MET overexpression/amplification after progression on Tagrisso.
- Safety profile consistent with known profiles of each medicine; no new safety findings.
- Data to be presented at forthcoming medical meeting and shared with global regulatory authorities.
- Tagrisso plus Orpathys already approved in China for this indication based on SACHI Phase III; temporary authorization granted in Switzerland based on SAVANNAH Phase II.
- Orpathys is jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.
Financial Impact
Positive read-through for Tagrisso franchise (AstraZeneca's top-selling drug) and Orpathys; potential to address ~34% of Tagrisso progressors who develop MET-driven resistance; supports global label expansion and revenue upside.
Risk Factors
- Regulatory timelines and approval decisions outside China are uncertain.
- Competing MET-targeted therapies (e.g., amivantamab combinations) could limit market share.
- Pricing and reimbursement dynamics for combination therapy may affect adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007677 |
| Document: 0001654954-26-007677-index-headers.html | 0001654954-26-007677 |
| Document: 0001654954-26-007677-index.html | 0001654954-26-007677 |
| Document: 0001654954-26-007677.txt | 0001654954-26-007677 |
Track record
77 reports on AZN
18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers